Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

MTNB vs EQ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EQ Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)

EQ Overall Winner 6-Pillar Tally: MTNB 1 – 4 EQ (1 Tie) Matrix Metrics: MTNB 2 – 6 EQ

As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-52.3% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MTNB vs EQ
MTNB NYSE American
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.81
-10.98% 1D
Market Cap $979,904
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -7.20β · 147% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 53.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 33.0 · SMA20: $1.26 · SMA50: $1.47
EQ NASDAQ Head-to-Head Winner
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap $90.6M
TTM Revenue $4.4M
Forward P/E 1.5x
Beta / 30D Vol 1.53β · 93% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.8%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $1.33 · SMA50: $1.49

6-Pillar Scorecard Institutional Category Breakdown (MTNB 1 – 4 EQ)

Columns: Metric · MTNB · EQ
1. Valuation Multiples EQ
Forward P/E N/M 1.5x
Trailing P/E N/M 1.5x
PEG Ratio N/M N/M
EV / Revenue N/M 7.7x
2. Growth & Scale EQ
Revenue Growth (YoY) -100.0% -52.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $4.4M
Market Cap $979,904 $90.6M
3. Profitability & Quality EQ
Gross Margin N/A 100.0%
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -147.5% -59.0%
4. Balance Sheet & Cash Flow MTNB
Cash Generation (TTM) N/A -$20M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.2M Net Cash $57M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EQ
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 261.3% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MTNB (2) vs EQ (6)
Institutional Metric MTNB EQ Criterion Row Edge
Market Capitalization
Scale
$979,904 $90.6M Larger Scale EQ
Trailing P/E Ratio
Valuation
N/M 1.5x Lower Multiple EQ
Forward P/E Ratio
Valuation
N/M 1.5x Lower Multiple EQ
Revenue Growth (YoY)
Growth
-100.0% -52.3% Higher Growth EQ
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-147.5% -59.0% Higher ROE EQ
52-Week Range Position
Momentum
22% ($0–$3) 11% ($1–$4) Stronger Trend MTNB
Beta / 30D Volatility
Risk Regime
-7.20β · 147% Vol 1.53β · 93% Vol Lower Realized Risk EQ
Unified Institutional Score
Composite Signal
54.6 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite MTNB
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.2M Net Cash) -$20M ($57M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EQ +25.57 pp
MTNB: -46.7% · EQ: -21.13%
3M Horizon MTNB +359.01 pp
MTNB: +307.49% · EQ: -51.52%
6M Horizon MTNB +70.25 pp
MTNB: +20.93% · EQ: -49.32%
1Y Horizon EQ +43.35 pp
MTNB: -31.35% · EQ: +12.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MTNB Revenue EQ Revenue MTNB Op. Margin EQ Op. Margin Margin Leader
FY2017 $0M N/A -11024.6% N/A MTNB
FY2018 $0M N/A -12230.9% N/A MTNB
FY2019 $0M N/A -21067.4% N/A MTNB
FY2020 $0M N/A -15288.4% N/A MTNB
FY2021 $0M N/A -74954.5% N/A MTNB
FY2022 $0M $20M -771.3% -393.9% EQ
FY2023 $0M $40M -2168.4% -40.2% EQ
FY2024 N/A $40M N/A -20.1% EQ

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MTNB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EQ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 261.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MTNB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EQ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $90.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MTNB vs EQ Key Questions & Quantitative Answers

As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-52.3% vs. -100.0% YoY). Technical & Structure Timing Caution: MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EQ leads the Growth & Scale pillar: MTNB posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EQ at -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2024), MTNB cumulative revenue shifted N/A while EQ shifted +100.0%. In operating R&D and SG&A reinvestment, MTNB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EQ.

EQ screens cheaper on headline valuation multiples. MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MTNB (-147.5% ROE) versus EQ (-59.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk). By comparison, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.